An independent study by Pauly et al., demonstrated that there were 81.4% (22 out of 27) of endometrial carcinoma patients who had hMLH1 loss or microsatellite instability and showed hMLH1 promoter hypermethylation [31]. Here, MLH1 is linked to endometrial carcinoma.